Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients
Open Access
- 8 June 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 18 (1), 1-12
- https://doi.org/10.1186/s12885-018-4566-4
Abstract
This study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization (DEB-TACE) treatment by CalliSpheres® in Chinese patients with hepatocellular carcinoma (HCC) as well as the predicting factors for response. 99 patients with HCC were consecutively enrolled in this study. All participants were treated by CalliSpheres® DEB-TACE. Clinical response was evaluated according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Common Terminology Criteria for Adverse Events (CTCAE) was used to assess the adverse events and liver dysfunction during and after the operation. Post treatment, 16 patients (16.2%) achieved CR and 59 (59.6%) achieved PR, the ORR was 75.8%. Subgroup analysis showed that patients with higher BCLC stage were of worse CR and ORR rates, and the CR as well as ORR between patients with cTACE history and patients without cTACE history were similar. Univariate logistic regression analysis displayed that number of nodules > 3, higher BCLC stage and previous cTACE might be correlated with worse ORR but with no statistical significance. As to liver function, CTCAE grades of laboratory indexes for liver function were increased at 1 week compared to baseline and recovered to the baseline grades at 1–3 months post operation. Besides, most of the common adverse events were light and moderate in our study. In conclusion, DEB-TACE by CalliSpheres® was efficient and well tolerated in Chinese HCC patients, and BCLC stage, number of nodules and cTACE history were possibly correlated with treatment response.Keywords
Funding Information
- National Natural Science Foundation of China (81371658, 81572307)
- Zhejiang Provincial Natural Science Foundation of China (LZ18H180001)
- Medical Health Fund of Zhejiang Province (2013KYB097)
- Basic Health Appropriate Technology for the Transformation of Major Projects during the 12th Five-Year Plan Period of Zhejiang Province (2013T301-15)
- Major Project of Medical and Health Technology Development Program in Zhejiang Province (7211902)
- National Key Basic Research Development Program (2013CB531403)
- Science and Technology Major Project of Zhejiang Province (2014C13G2010059)
This publication has 32 references indexed in Scilit:
- Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian CenterJournal of Vascular and Interventional Radiology, 2017
- Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular CarcinomaJournal of Computer Assisted Tomography, 2017
- Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsionEuropean Radiology, 2016
- Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinomaWorld Journal of Gastroenterology, 2016
- Prognosis of Early-Stage Hepatocellular CarcinomaMedicine, 2015
- A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2015
- Transarterial Chemoembolization Using Gelatin Sponges or Microspheres Plus Lipiodol-Doxorubicin versus Doxorubicin-Loaded Beads for the Treatment of Hepatocellular CarcinomaKorean Journal of Radiology, 2015
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999